UOC
PTGX icon

UBS O'Connor’s Protagonist Therapeutics PTGX Stock Holding History

UBS O'Connor’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,523
Closed -$803K – 414
2025
Q2 		$803K Buy
14,523
+1,183
+9% +$56.8K 0.02% 247
2025
Q1 		$645K Buy
+13,340
New +$559K 0.02% 214
2024
Q3 		– Sell
-68,231
Closed -$2.76M – 587
2024
Q2 		$2.36M Sell
68,231
-41,099
-38% -$1.2M 0.07% 173
2024
Q1 		$3.16M Buy
109,330
+3,176
+3% +$86.4K 0.09% 121
2023
Q4 		$2.43M Sell
106,154
-30,114
-22% -$527K 0.08% 148
2023
Q3 		$2.27M Buy
136,268
+69,174
+103% +$1.34M 0.04% 223
2023
Q2 		$1.85M Sell
67,094
-41,379
-38% -$1.04M 0.04% 310
2023
Q1 		$2.49M Sell
108,473
-168,000
-61% -$2.82M 0.06% 236
2022
Q4 		$3.02M Buy
276,473
+43,653
+19% +$368K 0.06% 309
2022
Q3 		$1.96M Buy
232,820
+13,000
+6% +$123K 0.02% 628
2022
Q2 		$1.74M Buy
219,820
+179,820
+450% +$2.17M 0.02% 682
2022
Q1 		$947K Buy
+40,000
New +$1.13M 0.01% 705

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS O'Connor's PTGX Position: Q3 2025 in Review

UBS O'Connor sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 14,523 shares — an estimated $803K sold.

UBS O'Connor first reported a position in PTGX in Q1 2022 and held it in 12 quarters. The position peaked at $3.16M in Q1 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • UBS O'Connor reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 14,523 Protagonist Therapeutics shares in Q3 2025, an estimated $803K.
  • UBS O'Connor first reported a position in Protagonist Therapeutics in Q1 2022 and held it in 12 quarters.
  • UBS O'Connor's Protagonist Therapeutics position peaked at $3.16M in Q1 2024.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.